Adenomyosis Market Research Report – Forecast to 2027

Adenomyosis Market Information: Type (Focal, Adenomyoma), Treatment (Anti-Inflammatory Drugs, Hormone Medications), Diagnosis (Ultrasound, MRI), and End-User (Hospitals & Clinics, Ambulatory Surgical Center, Research Institute) – Global Forecast Till 2027

ID: MRFR/Pharma/4597-HCR | August 2022 | Region: Global | 100 Pages         

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Adenomyosis Market, by Type

6.1 Introduction

6.2 Focal

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

6.3 Adenomyoma

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

6.4 Diffuse

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7. Global Adenomyosis Market, by Treatment

7.1 Introduction

7.2 Anti-Inflammatory Drugs

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.2.1 Ibuprofen

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.2.2 Naproxen

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.3 Hormone Medications

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.3.1 Combined Estrogen-Progestin Pills

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.3.2 Vaginal Rings

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.3.3 Hormone-Containing Patches

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.3.4 Aromatase Inhibitors

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

•

7.4 Hysterectomy

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8. Global Adenomyosis Market, by Diagnosis

8.1 Introduction

8.2 Ultrasound

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8.3 MRI

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8.4 Historiography

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8.5 Hysteroscopy

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8.6 Cystoscopy

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8.7 Laparoscopy

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9. Global Adenomyosis Market, by End-User

9.1 Introduction

9.2 Hospitals & Clinics

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9.3 Ambulatory Surgical Centers

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9.4 Research Institutes

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9.5 Others

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

10 Global Adenomyosis Market, by Region

10.1 Introduction

10.2 Americas

• Market Estimates & Forecast, by Region, 2020–2027

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.1 North America

• Market Estimates & Forecast, by Country, 2020–2027

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.1.1 U.S.

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.1.2 Canada

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.2 South America

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3 Europe

• Market Estimates & Forecast, by Region, 2020–2027

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1 Western Europe

• Market Estimates & Forecast, by Country, 2020–2027

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.1 Germany

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.2 France

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.3 U.K.

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.4 Italy

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.5 Spain

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.6 Rest of Western Europe

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.2 Eastern Europe

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4 Asia Pacific

• Market Estimates & Forecast, by Country, 2020–2027

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.1 Japan

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.2 China

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.3 India

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.4 Australia

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.5 Republic of Korea

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.6 Rest of Asia Pacific

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5 The Middle East & Africa

• Market Estimates & Forecast, by Region, 2020–2027

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.1 United Arab Emirates

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.2 Saudi Arabia

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.3 Oman

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.4 Kuwait

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.5 Qatar

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.6 Rest of the Middle East & Africa

• Market Estimates & Forecast, by Type, 2020–2027

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Diagnosis, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Bayer AG

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Ferring B.V.

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Johnson & Johnson Consumer Inc.

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Novartis

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Merck KGaA

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Pfizer Inc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Specialty European Pharma

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Urit Medical Electronic Group Co., Ltd

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Roche Diagnostics

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Danaher Corporation

12.10.1 Overview

12.10.2 Product Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.12 Sysmex Corporation

12.12.1 Overview

12.12.2 Product Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.12 Acon Laboratories, Inc.

12.12.1 Overview

12.12.2 Product Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.13 Elektronika Kft.

12.13.1 Overview

12.13.2 Product Overview

12.13.3 Financials

12.13.4 Key Developments

12.13.5 SWOT Analysis

12.14 Mindray Medical International Limited

12.14.1 Overview

12.14.2 Product Overview

12.14.3 Financials

12.14.4 Key Developments

12.14.5 SWOT Analysis

12.15 Arkray, Inc.

12.15.1 Overview

12.15.2 Product Overview

12.15.3 Financials

12.15.4 Key Developments

12.15.5 SWOT Analysis

13 Appendix

LIST OF TABLES

Table 1 Adenomyosis Industry Synopsis, 2020–2027

Table 2 Global Adenomyosis Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Global Adenomyosis Market, by Region, 2020–2027, (USD Million)

Table 4 Global Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 5 Global Adenomyosis Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Global Adenomyosis Market, by End-User, 2020–2027, (USD Million)

Table 7 North America Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 8 North America Adenomyosis Market, by Diagnosis, 2020–2027, (USD Million)

Table 9 North America Adenomyosis Market, by End-User, 2020–2027, (USD Million)

Table 10 U.S. Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 11 U.S. Adenomyosis Market, by Diagnosis, 2020–2027, (USD Million)

Table 12 U.S. Adenomyosis Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 14 Canada Adenomyosis Market, by Diagnosis, 2020–2027, (USD Million)

Table 15 Canada Adenomyosis Market, by End-User, 2020–2027, (USD Million)

Table 16 South America Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 17 South America Adenomyosis Market, by End-User, 2020–2027, (USD Million)

Table 18 Europe Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 19 Europe Adenomyosis Market, by End-User, 2020–2027, (USD Million)

Table 20 Western Europe Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 21 Western Europe Adenomyosis Market, by End-User, 2020–2027, (USD Million)

Table 22 Eastern Europe Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 23 Eastern Europe Adenomyosis Market, by End-User, 2020–2027, (USD Million)

Table 24 Asia Pacific Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 25 Asia Pacific Adenomyosis Market, by End-User, 2020–2027, (USD Million)

Table 26 Middle East & Africa Adenomyosis Market, by Treatment, 2020–2027, (USD Million)

Table 27 Middle East & Africa Adenomyosis Market, by diagnosis, 2020–2027, (USD Million)

Table 28 Middle East & Africa Adenomyosis Market, by End-User, 2020–2027, (USD Million)

 

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Adenomyosis Market

Figure 3 Segmentation Market Dynamics for Adenomyosis Market

Figure 4 Global Adenomyosis Market Share, by Treatment, 2020

Figure 5 Global Adenomyosis Market Share, by Diagnosis, 2020

Figure 6 Global Adenomyosis Market Share, by End-User, 2020

Figure 7 Global Adenomyosis Market Share, by Region, 2020

Figure 8 North America Adenomyosis Market Share, by Country, 2020

Figure 9 Europe Adenomyosis Market Share, by Country, 2020

Figure 10 Asia Pacific Adenomyosis Market Share, by Country, 2020

Figure 11 Middle East & Africa Adenomyosis Market Share, by Country, 2020

Figure 12 Global Adenomyosis Market: Company Share Analysis, 2020 (%)

Figure 13 Merck KGaA: Key Financials

Figure 14 Merck KGaA: Segmental Revenue

Figure 16 Merck KGaA: Geographical Revenue

Figure 17 Pfizer, Inc.. Key Financials

Figure 18 Pfizer, Inc.: Segmental Revenue

Figure 19 Pfizer, Inc.: Geographical Revenue

Figure 20 Danaher Corporation: Key Financials

Figure 21 Danaher Corporation: Segmental Revenue

Figure 22 Danaher Corporation: Geographical Revenue

Figure 23 Bayer AG: Key Financials

Figure 24 Bayer AG: Segmental Revenue

Figure 25 Bayer AG: Geographical Revenue

Figure 26 Novartis AG: Key Financials

Figure 27 Novartis AG: Segmental Revenue

Figure 28 Novartis AG. Geographical Revenue

Figure 29 Roche Diagnostic. Key Financials

Figure 30 Roche Diagnostic. Segmental Revenue

Figure 31 Roche Diagnostic. Geographical Revenue

Adenomyosis Market Scenario


The adenomyosis market is expected to register a CAGR of 4.5% during the forecast period, 2018–2023. The adenomyosis market is majorly driven by the high prevalence of urinary tract infections, rise in fibroid removal surgeries, increasing infection rates, rising population of women aged 40 and above, rising demand for technical advancements, increasing number of regulatory approvals, and growing penetration by market players. Additionally, factors such as the increasing funding for research and development initiatives in advanced medical treatment options are likely to drive the market. However, factors such as lack of awareness regarding causes and symptoms of adenomyosis are likely to hamper the growth of the market.


Market Segmentation                                                                                                                          


The adenomyosis market is segmented on the basis of type, treatment, diagnosis, and end-user. Considering type, the market is segmented into focal, adenomyoma, and diffuse. With reference to treatment, the market is segmented into anti-inflammatory drugs, hormone medications, and hysterectomy.  By anti-inflammatory drugs, the market is sub-segmented into ibuprofen and naproxen. By hormone medications, the market is segmented into combined estrogen-progestin pills, vaginal rings, hormone-containing patches, and aromatase inhibitors. Based on diagnosis, the market is segmented into ultrasound, MRI, historiography, hysteroscopy, cystoscopy, and laparoscopy. By end-user, the market is segmented into hospitals and clinics, research institutes and ambulatory surgical centers, and others. Based on region, the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.


Regional Market Summary


North America is expected to hold the largest share of the adenomyosis market during the forecast period 2018–2023. The increasing prevalence of urinary tract infection is likely to enhance the growth of adenomyosis. Additionally, factors such as increasing government initiatives and funding for research and development in advanced medical treatment options along with the rising demand for technologically advanced treatments are likely to enhance the growth of the adenomyosis market in North America. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases, urinary infections are the most common bladder infections, and at least 40 to 60%of women develop a UTI during their lifetime.


Adenomyosis is a disease that occurs in women during their childbearing years. This disease is said to affect the mid-aged women and women who have had children. Women aged 40 and above are more prone to contract adenomyosis. According to the American U.S. Bureau, in 2016, around 10.57 million women were aged 40 and above. Additionally, according to the Government of Canada, in 2014 Canadas’ population comprised of 17.9 million females. This huge population of women aged 40 and above is expected to have a direct effect on the adenomyosis market as adenomyosis is known to affect mid-age women.


Europe is the second largest market and is expected to hold a healthy share in the adenomyosis market during the forecast period 2018–2023. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with the growing need for better healthcare infrastructure. Furthermore, increasing older women population along with the increasing prevalence of urinary infections is driving the growth of the adenomyosis market in Europe.


Asia Pacific is expected to be the fastest growing market. Factors such as the increasing prevalence of inflammatory disorders and injuries are the major drivers for the market growth. China is expected to be the fastest growing country due to increasing population and raising awareness about the health and availability of new treatment methods. Moreover, rising healthcare expenditure and improvement in the standard of living are driving the growth of the adenomyosis market in the Asia Pacific region.


The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and rising availability of specialty care centers.


Research Methodology:


Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, technology assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.


Market Segmentation & Key players


Adenomyosis Market, by Type



  • Focal Physiotherapy

  • Adenomyoma

  • Diffuse


Adenomyosis Market, by Treatment



  • Anti-Inflammatory Drugs

  • Ibuprofen

  • Naproxen

  • Hormone Medications

  • Combined estrogen-progestin pills

  • Vaginal rings

  • Hormone-containing patches

  • Aromatase inhibitors

  • Hysterectomy


Adenomyosis Market, by Diagnosis



  • Ultrasound

  • MRI

  • Historiography

  • Hysteroscopy

  • Cystoscopy

  • Laparoscopy


Adenomyosis Market, by End-user



  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Research Institutes

  • Others


Adenomyosis Market, by Region


North America



  • U.S.

  • Canada


South America


Europe



  • Western Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Spain

  • Rest of Western Europe

  • Eastern Europe


Asia Pacific



  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia Pacific


Middle East and Africa



  • United Arab Emirates

  • Saudi Arabia

  • Oman

  • Kuwait

  • Qatar

  • Rest of the Middle East & Africa


Market Players



  • Bayer AG

  • Novartis AG

  • Pfizer, Inc.

  • Johnson & Johnson Services, Inc.

  • Siemens Healthcare Scientific Ltd.

  • Ferring B.V.

  • Merck KGaA

  • Specialty European Pharma

  • Urit Medical Electronic Group Co., Ltd

  • Roche Diagnostics

  • Danaher Corporation

  • Sysmex Corporation

  • Acon Laboratories, Inc.

  • Mindray Medical International Limited

  • Arkray, Inc.

  • Elektronika Kft.


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


 

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Major treatments for adenomyosis include hormone medications and anti-inflammatory drugs.

Global adenomyosis market is expected to exhibit a strong 4.5% CAGR over the forecast period from 2020 to 2027.

The rising prevalence of urinary tract infections is the major driver for the adenomyosis market.

North America holds the largest share in the adenomyosis market.

Leading players in the adenomyosis market include Bayer, Novartis, and Pfizer, among others.